Fate Therapeutics (FATE) Tops Q2 EPS by 5c, misses on revenue

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.54), $0.05 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $930 thousand versus the consensus estimate of $5.41 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• Optex Systems Holdings, Inc. (OPXS) Misses Q3 EPS by 2c
• Hour Loop, Inc. (HOUR) Reports Q2 EPS of $0.03